TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in HgbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Muscle Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: locomotor efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eye control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary Vascular Remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Oswestry disability index scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detection of occult invasive cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 20 Meter Push Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Push Test - Metabolic (kCal/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mobility-Related ADL - Timed (seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2/FIO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative analgesia and sedation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Slow Wave Sleep (SWS) duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Counter movement vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wingate anaerobic cycle ergometer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's pre-operative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent's pre-operative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pain during propofol injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with surgically removed needle fragment retentions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Primary Care Provider Visit Attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with unsafe swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with impaired swallowing efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with delayed airway closure (Time-to-laryngeal-vestibule-closure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with poor pharyngeal constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women without levator ani muscle co-activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Infants' adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mothers' incremental area under glucose response curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbar radicular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health related quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Number of Awakenings After Sleep Onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Knowledge of CSA prevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude toward prevention of Sexual abuse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Practice of CSA prevention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Awareness of CSA prevention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Hematologic improvement based on erythroid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood alcohol concentrations (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration for Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) from time 0 up to time t (AUC0-t) for Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 and extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of preterm births
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incidence of intrauterine growth restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Feasibility of Continuous Glucose Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturia frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of MODY monogenic diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ASEPSIS wound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: histological response according to Ryan classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The System Usability Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Net Promoter Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The Subjective Feedback Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with Implant-loss
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Covid19
Endpoint domain: Mortality/survival
Primary endpoint: Vt of [11C]UCB-J
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vt of [18F]SynVest-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of grade 3-5 adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Related Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Subject safety
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in 10 Metre Walk Test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of a vEDS-related clinical event requiring medical attention
Endpoint domain: Mortality/survival
Primary endpoint: Change in Asthma quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Contact tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participant heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in participant electrodermal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKPS (Kujala Scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FPI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DVI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Early-stage pancreatic cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal oxygen uptake (VO2pic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 Specific Immunoglobulin (Ig)G Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantity of patient-generated health data collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Seroprevalence of antibodies in health care professionals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain MCID
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: amount of expressed milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with critical events related to intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who accepted intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of intervention completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants screening positive for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: V'O2-adjusted plasma lactate profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of NRS Responders at Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Connection Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Spinal Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of parents management of children's pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment-related Grade 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Viral rebound before or at week 24 post withdrawing ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IVH severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: EVD obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Force-Velocity Profile (F-V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sprint spatiotemporal and kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptability and tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: High flow oxygen failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early Engagement in B/N Treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline in duration of non-rapid eye movement (NREM) sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Diagnosis of Eating Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregation pattern of a-synuclein, amyloid-b, p-TAU and TDP-43
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24h mean arterial blood pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of average ALT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Difference of average ALP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Leukocyte metabolic gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Temporomandibular disorders (TMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk angle at touchdown of the first recovery step
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year metastasis-free survival (MFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Planning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effort decision making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of viable germinal elements of echinococcosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of patients who accept/refuse the treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: physiotherapy compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: falls or event near falling occurred during rehabilitation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) and recommended phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain Quality Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Morphine Equivalents (TME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of preventive health services utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of ABBV-1088
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of tap water safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plain water intake (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h urine osmolality (mmol/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total molar distalization distance by mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of detected lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Inhibitory Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: shade match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final evaluation of application field tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Galectin-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Sedation State Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of [18F]-C-SNAT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cognitive dysfunction (POCD) measured by MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative cognitive dysfunction (POCD) measured by DSST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative inflammation measured by serum CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative inflammation measured by white blood cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative inflammation measured by serum IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extent of HA accumulation in shoulder muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distinction between latent versus active PSSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in ESSDAI at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the KCCQ Clinical Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric mean titer (GMT) of gE-specific total IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety in terms of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Safety in terms of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Safety in terms of laboratory-based AEs
Endpoint domain: Adverse events/effects
Primary endpoint: subjective sleep change
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: objective sleep change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-SARS-CoV-2 Spike IgG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety of the rapid discharge protocol
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy of the rapid discharge protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year cumulative incidence of myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in disease activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term unresponsiveness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of identifying LRTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amount of Root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle capillarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Serious Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Local Reactions and Systemic Reactions (The First Vaccination)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Local Reactions and Systemic Reactions (The Second Vaccination)
Endpoint domain: Adverse events/effects
Primary endpoint: change in irisin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in myostatin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in decorin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to claudication pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of Risankizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve (AUC) of Risankizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicidal ideation and behaviour scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton-Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hamilton-Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Variation in mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants completing all study procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Plasma Concentration (Cmax) of capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of eligible patients screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the number of eligible patients referred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Distress menstrual
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: additional sick leave free days alive
Endpoint domain: Mortality/survival
Primary endpoint: Dyspnea Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cough and Sputum Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spirometry (FEV1 and FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum level of Kisspeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum levels of Lipoxin A4 (LXA4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing at least 80% of the healthy population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening in clinical reference test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of 3D-MRE and 2D-MRE for assessing portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes